Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: A step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 1, 2015, Pages 198-206

  Cojutti, Piergiorgio ^a,b   Maximova, Natalia ^c   Crichiutti, Giovanni ^a   Isola, Miriam ^b   Pea, Federico ^a,b  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

Drug interactions; Drug underexposure; MDR staphylococci; Oxazolidinones

Indexed keywords

AMIODARONE; ANTINEOPLASTIC AGENT; HEMOGLOBIN; LINEZOLID; PHENOBARBITAL; PROTON PUMP INHIBITOR; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATE; BONE AND JOINT INFECTIONS; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM INFECTION; CHILD; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG MONITORING; FEMALE; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZED CHILD; HUMAN; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PNEUMONIA; PRESCHOOL CHILD; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SCHOOL CHILD; THROMBOCYTE COUNT; TREATMENT DURATION; CHEMISTRY; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITAL PATIENT; HOSPITALIZATION; INFANT; PLASMA; TERTIARY CARE CENTER;

ACETAMIDES; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DRUG MONITORING; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HOSPITALIZATION; HUMANS; INFANT; INPATIENTS; MALE; MONTE CARLO METHOD; OXAZOLIDINONES; PLASMA; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84928344537     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku337     Document Type: Article

References (59)

1. Weisman LE. Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient. Curr Opin Infect Dis 2004; 17: 237-41.
2. Hermos CR, Sandora TJ, Williams LE et al. Changing epidemiology of methicillin-resistant Staphylococcus aureus colonization in paediatric intensive-care units. Epidemiol Infect 2013; 141: 1983-92.
3. Raymond J, Aujard Y. Nosocomial infections in pediatric patients: a European, multicenter prospective study. European Study Group. Infect Control Hosp Epidemiol 2000; 21: 260-3.
4. Richards MJ, Edwards JR, Culver DH et al. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Pediatrics 1999; 103: e39.
5. Lessa FC, Edwards JR, Fridkin SK et al. Trends in incidence of late-onset methicillin-resistant Staphylococcus aureus infection in neonatal intensive care units: data from the National Nosocomial Infections Surveillance System, 1995-2004. Pediatr Infect Dis J 2009; 28: 577-81.
6. Cosseron-Zerbib M, Roque Afonso AM, Naas Tet al. A control programme for MRSA (methicillin-resistant Staphylococcus aureus) containment in a paediatric intensive care unit: evaluation and impact on infections caused by other micro-organisms. J Hosp Infect 1998; 40: 225-35.
7. Raymond J, Nordmann P, Doit C et al. Multidrug-resistant bacteria in hospitalized children: a 5-year multicenter study. Pediatrics 2007; 119: e798-803.
8. Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin 2010; 26: 571-88.
9. Peppard WJ, Johnston CJ, Urmanski AM. Pharmacologic options for CNS infections caused by resistant Gram-positive organisms. Expert Rev Anti Infect Ther 2008; 6: 83-99.
10. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-40.
11. Pea F, Furlanut M, Cojutti P et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010; 54: 4605-10.
12. Gandelman K, Zhu T, Fahmi OA et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2011; 51: 229-36.
13. Bolhuis MS, van Altena R, Uges DR et al. Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 2010; 54: 5418-9.
14. Dong H, Wang X, Dong Y et al. Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 2011; 38: 296-300.
15. Boak LM, Rayner CR, Grayson ML et al. Clinical population pharmacokinetics and toxicodynamics of linezolid. Antimicrob Agents Chemother 2014; 58: 2334-43.
16. Pea F, Viale P, Cojutti P et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 2012; 67: 2034-42.
17. Kearns GL, Abdel-Rahman SM, Blumer JL et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000; 19: 1178-84.
18. Jungbluth GL, Welshman IR, Hopkins NK. Linezolid pharmacokinetics in pediatric patients: an overview. Pediatr Infect Dis J 2003; 22 Suppl: S153-7.
19. Porta A, Esposito S, Menson E et al. Off-label antibiotic use in children in three European countries. Eur J Clin Pharmacol 2010; 66: 919-27.
20. Hersh AL, Lee BR, Hedican EB et al. Linezolid use in hospitalized children. Pediatr Infect Dis J 2014; 33: e14-8.
21. Simon A, Mullenborn E, Prelog M et al. Use of linezolid in neonatal and pediatric inpatient facilities-results of a retrospective multicenter survey. Eur J Clin Microbiol Infect Dis 2012; 31: 1435-42.
22. Gostelow M, Gonzalez D, Smith PB et al. Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. Expert Rev Clin Pharmacol 2014; 7: 327-40.
23. Kocher S, Muller W, Resch B. Linezolid treatment of nosocomial bacterial infection with multiresistant Gram-positive pathogens in preterm infants: a systematic review. Int J Antimicrob Agents 2010; 36: 106-10.
24. Ioannidou M, Apostolidou-Kiouti F, Haidich AB et al. Efficacy and safety of linezolid for the treatment of infections in children: a meta-analysis. Eur J Pediatr 2014; doi:10.1007/s00431-014-2307-5.
25. Garazzino S, Tovo PA. Clinical experience with linezolid in infants and children. J Antimicrob Chemother 2011; 66 Suppl 4: iv23-41.
26. Chiappini E, Conti C, Galli L et al. Clinical efficacy and tolerability of linezolid in pediatric patients: a systematic review. Clin Ther 2010; 32: 66-88.
27. Dotis J, Iosifidis E, IoannidouMet al. Use of linezolid in pediatrics: a critical review. Int J Infect Dis 2010; 14: e638-48.
28. Pea F, Dose L, Cojutti P et al. Educational and organizational interventions to improve the usefulness of clinical pharmacological advice for personalized drug dosing based on therapeutic drug monitoring. Basic Clin Pharmacol Toxicol 2014; doi:10.1111/bcpt.12249.
29. Lacarelle B, Pisano P, Gauthier Tet al. Abbott PKS system: a new version for applied pharmacokinetics including Bayesian estimation. Int J Biomed Comput 1994; 36: 127-30.
30. Andes D, van Ogtrop ML, Peng J et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 46: 3484-9.
31. Rayner CR, Forrest A, Meagher AK et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-23.
32. Mendes RE, Hogan PA, Streit JM et al. Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: report of linezolid activity over 9 years (2004-12). J Antimicrob Chemother 2014; 69: 1582-8.
33. Peng GW, Stryd RP, Murata S et al. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 1999; 20: 65-73.
34. Portier K, Tolson JK, Roberts SM. Body weight distributions for risk assessment. Risk Anal 2007; 27: 11-26.
35. Dong H, Xie J, Chen L et al. Developments in the pharmacokinetic/pharmacodynamic index of linezolid: a step toward dose optimization using Monte Carlo simulation in critically ill patients. Int J Infect Dis 2014; 22: 35-40.
36. Schwartz GJ, Munoz A, Schneider MF et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629-37.
37. Takahashi Y, Takesue Y, Nakajima K et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother 2011; 17: 382-7.
38. Castagnola E, Amoroso L, Banov L et al. Activity of linezolid and daptomycin against methicillin-resistant coagulase-negative staphylococci with increased MIC for vancomycin isolated from blood cultures in pediatric patients. J Chemother 2013; doi:10.1179/1973947813Y.0000000134.
39. Morata L, Cuesta M, Rojas JF et al. Risk factors for a low linezolid trough plasma concentration in acute infections. Antimicrob Agents Chemother 2013; 57: 1913-7.
40. Adembri C, Fallani S, Cassetta MI et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008; 31: 122-9.
41. Kosaka T, Kokufu T, Shime N et al. Pharmacokinetics and tolerance of linezolid for meticillin-resistant Staphylococcus aureus mediastinitis in paediatric patients. Int J Antimicrob Agents 2009; 33: 368-70.
42. Santos RP, Prestidge CB, Brown ME et al. Pharmacokinetics and pharmacodynamics of linezolid in children with cystic fibrosis. Pediatr Pulmonol 2009; 44: 148-54.
43. Egle H, Trittler R, Kummerer K et al. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 2005; 77: 451-3.
44. Matheny CJ, Lamb MW, Brouwer KR et al. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy 2001; 21: 778-96.
45. Katoh M, Nakajima M, Yamazaki H et al. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 2001; 12: 505-13.
46. Pauli-Magnus C, Rekersbrink S, Klotz U et al. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 551-7.
47. Callaghan R, Crowley E, Potter S et al. P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 2008; 48: 365-78.
48. Slatter JG, Stalker DJ, Feenstra KL et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [14C]linezolid to healthy human subjects. Drug Metab Dispos 2001; 29: 1136-45.
49. Matsumoto K, Takeshita A, Ikawa K et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 2010; 36: 179-81.
50. Cossu AP, Musu M, Mura P et al. Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature. Eur J Clin Pharmacol 2014; 70: 23-8.
51. Nukui Y, Hatakeyama S, Okamoto K et al. High plasma linezolid concentration and impaired renal function affect development of linezolidinduced thrombocytopenia. J Antimicrob Chemother 2013; 68: 2128-33.
52. Balayssac D, Authier N, Cayre A et al. Does inhibition of P-glycoprotein lead to drug-drug interactions? Toxicol Lett 2005; 156: 319-29.
53. Downes KJ, Hahn A, Wiles J et al. Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics. Int J Antimicrob Agents 2014; 43: 223-30.
54. Swoboda S, Ober MC, Lichtenstern C et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010; 66: 291-8.
55. Cattaneo D, Orlando G, Cozzi V et al. Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections. Int J Antimicrob Agents 2013; 41: 586-9.
56. Pea F, Cojutti P, Pagotto A et al. Successful long-term treatment of cerebral nocardiosis with unexpectedly low doses of linezolid in an immunocompromised patient receiving complex polytherapy. Antimicrob Agents Chemother 2012; 56: 3438-40.
57. Sasaki T, Takane H, Ogawa K et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother 2011; 55: 1867-73.
58. Hiraki Y, Tsuji Y, HiraikeMet al. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis 2012; 44: 60-4.
59. Tsuji Y, Hiraki Y, Matsumoto K et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother 2011; 17: 70-5.